Trapped without a diagnosis: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) by Kirresh, A et al.
A DIFFICULT CASE 
Trapped without a diagnosis: a case report of a relapsing remitting disorder causing 
transient paraparesis 
Ali Kirresh1, Alex Everitt1, Onn Min Kon1, Ranan DasGupta1, Matthew C. Pickering2, 
Helen J Lachmann3 
1Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, United Kingdom 
2Centre for Complement and Inflammation Research, Imperial College, London, 
United Kingdom 
3National Amyloidosis Centre, University College London, Royal Free Hospital, London, 
United Kingdom 
 
Corresponding author: Dr Ali Kirresh, Imperial College NHS Trust, St Mary’s Hospital, 
London, W2 1NY; ali.kirresh@doctors.org.uk 
 
Keywords: paraparesis, TRAPS, periodic fever syndromes 
 
 
 
ABSTRACT  
Tumour necrosis factor receptor associated periodic syndrome (TRAPS) is an 
autosomal dominant condition caused by mutations in the TNFRSF1A gene. It is 
characterised by recurrent episodes of myalgia, followed by prolonged pyrexia, 
migratory rashes, headache, serositis, arthralgia, abdominal pain and periorbital 
oedema. We describe the case of a 49 year old patient who presented with a self-
limiting episode of paraparesis on a background of recurrent bouts of abdominal 
symptoms and headaches since childhood. He had a persistent inflammatory response 
associated with night sweats and weight loss. A diagnosis of TRAPS was made two 
years later when a mutation was identified in the TNFRSF1A gene. The patient’s 
symptoms and inflammatory response resolved dramatically following treatment with 
the interleukin-1 receptor antagonist anakinra.  
 
CASE REPORT 
A 49 year old right handed male presented with a 3 day history of bilateral leg 
weakness, altered sensation in both feet later ascending to the thighs, unsteadiness, 
urinary and faecal retention. A few days earlier he described transient severe left 
frontal and retro-orbital headache without photophobia. He had been bitten by a dog 
4 weeks earlier. 
He had a lifelong history of unexplained episodic abdominal pains. These episodes 
followed a typical pattern lasting up to 2 weeks and increased in frequency with age. 
During adulthood they were occurring every 2 to 3 months. An episode would start 
with headaches and a dull central abdominal pain. Over 24 hours he would develop 
severe abdominal cramps with abdominal distension. Resolution of the episode was 
preceded by diarrhoea. Investigations excluded autoimmune disease, porphyria and 
hereditary angioedema. During one of these episodes he was noted to have a marked 
acute phase response:  ESR 80-100 mm/hr and CRP 130 mg/L and an exploratory 
laparotomy revealed small bowel adhesions, inflamed small bowel mesentery and 
mildly reactive lymph nodes. Histology of resected bowel revealed inflammation only. 
Surgical history included: tonsillectomy, adenoidectomy, appendicectomy and 
bilateral inguinal hernia repairs.  
. His half sibling had biopsy confirmed pulmonary sarcoidosis. 
Examination revealed normal cranial nerves. His gait was ataxic but Romberg’s test 
was negative. Limb tone was normal. He had a mild paraparesis (hip flexion MRC 4/5, 
knee flexion 4+/5), symmetrically brisk reflexes in all four limbs, and bilateral extensor 
plantar responses. Abdominal reflexes were absent. He had mild bilateral heel-shin 
ataxia. Joint position sense was preserved but vibration sense was reduced below the 
sternum bilaterally. Pinprick sensation was reduced below T7. Anal tone was reduced. 
Neurological examination was otherwise unremarkable. A urethral catheter was 
inserted and there was a residual of greater than 500 millilitres. 
 
INVESTIGATIONS 
He had a marked acute phase response: CRP 230mg/L (NR<5), ESR 85 mm/hr; 
microcytic anaemia (Hb 111g/L, MCV 70fL), thrombocytosis (481x109/L, NR 150-400) 
and neutrophilia (9.8x109/L, NR 1.5-8). Normal or negative blood tests included: renal, 
liver and bone profiles, vitamin B12, folate, ANA, ANCA, rheumatoid factor, 
complement C3 and C4, antiphospholipid antibodies, anticardiolipin antibodies, 
serum ACE, LDH, JAK-2 mutation, AFP, CA19-9, CEA, and IgG subsets. Serological tests 
for HIV, syphilis, brucella, borrelia, toxocara, hepatitis B/C toxoplasma, yersinia, 
bartonella and atypical pneumonia were negative. T-spot.TB was non-reactive.  
MRI brain demonstrated multiple non-specific white matter lesions, reported as minor 
microangiopathic change (Figure 1). MRI whole spine excluded cord compression and 
revealed no cord signal change. Vertebral bone marrow was diffusely hypointense 
with multiple vertebral haemangiomata. Cerebrospinal fluid (CSF) was acellular with 
an elevated protein of 1.05g/L (NR 0.15-0.45), normal glucose differential, sterile 
culture (fungal and bacterial) and matched CSF/serum oligoclonal bands.  
A CT scan of the chest, abdomen and pelvis revealed diffuse lymphadenopathy with 
hepatosplenomegaly, signs of portal hypertension, prominent right renal pelvis and 
an inferior mesenteric vein (IMV) thrombosis. Inguinal lymph node aspiration revealed 
reactive changes only, without evidence of lymphoma or granulomatous 
inflammation. Bone marrow biopsy and trephine showed a hypercellular bone 
marrow aspirate with no lymphoid infiltrate.  
 
TREATMENT AND PROGRESS 
He was initially treated with ceftriaxone and metronidazole due to suspected sepsis. 
However, investigations did not reveal sepsis and his condition spontaneously 
improved over the next 2 weeks. Following exclusion of oesophageal varices on 
endoscopy, the patient was warfarinised for 6 months for the IMV thrombosis. He was 
discharged with a final diagnosis of self-limiting acellular transverse myelitis.  
His paroxysms of abdominal pain continued and were associated with weight loss. ESR 
and CRP remained persistently elevated. He continued to suffer from episodes of 
recurrent subacute small bowel obstruction due to small bowel adhesions. Whole 
body FDG-PET-CT scan 2 years after his neurological illness showed persistent diffuse 
lymphadenopathy; multiple loops of adherent thickened bowel in the left iliac fossa; 
increased peritoneal activity and free fluid. An omental biopsy showed acute 
inflammation and organizing adhesions, with negative cultures. Additional features 
included the development of a sterile right-sided pleural effusion and the appearance 
of epicardial calcification on imaging. 
In view of his recurrent unexplained symptoms, together with childhood onset, 
screening for the presence of a periodic fever associated genetic change was 
performed. This revealed a TNFRSF1A N65K mutation, confirming a diagnosis of 
Tumour Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) and 
excluded mutations in MEFV (the gene responsible for familial Mediterranean fever), 
MVK (the gene responsible for the mevalonate kinase deficiencies) and NOD2 (which 
can cause both familial Crohn’s and Blau syndrome).  
The patient was commenced on specific IL-1 blockade using anakinra, a recombinant 
IL-1 receptor antagonist, at a dose of 100 milligrams daily with complete normalisation 
of his acute phase response within 2 weeks and complete resolution of his systemic 
symptoms.  
 
DISCUSSION 
Tumour necrosis factor receptor associated periodic syndrome (TRAPS) is an 
autosomal dominant condition caused by mutations in the TNFRSF1A gene. It is 
characterised by recurrent episodes of myalgia, followed by prolonged pyrexia, 
migratory rashes, headache, serositis, arthralgia, abdominal pain and periorbital 
oedema. These episodes occur either spontaneously or following triggers such as 
stress or infection and usually last 1-3 weeks and recur monthly-yearly. More than 
10% of patients develop systemic amyloid AA amyloidosis, which confers a poor 
prognosis.[1] 
Mutations in the TNFRSF1A gene result in aberrant protein folding with accumulation 
in the endoplasmic reticulum. This causes both ER stress and increased production of 
reactive oxygen species and hence persistent inflammation.[2] In addition there is 
some evidence that the lack of TNF signalling may result in decreased activity in the 
NF-kappa beta transcription pathway, leading to a reduction in apoptosis and 
therefore prolonged survival of the activated inflammatory cells.[3] The effect is an 
excess production of cytokines such as interleukin-1 which promotes the release of a 
cascade of inflammatory cytokines.  
The patient in this case demonstrated many of the characteristic features of TRAPS. 
However, the presumed inflammatory transverse myelitis suspected in this case has 
not previously been described. It is not presently understood why only a small 
proportion of patients develop neurological symptoms. One possibility is that only 
some TNFRSF1A allelic mutations predispose to neurological involvement. The R92Q 
mutation is associated with TRAPS and an increased risk of multiple sclerosis. It is 
possible that this mutation results in an alteration of downstream signalling pathways, 
which may confer an increased susceptibility to neural tissue.[4]  
Chronic IL-1 stimulation within the central nervous system (CNS) is known to mediate 
several neuroinflammatory processes.[5] Within animal models, chronic IL-1 exposure 
within the CNS caused a marked recruitment of neutrophils, extensive demyelination 
and breakdown of the blood brain barrier (BBB).[6] The patient in this case 
demonstrated CSF albuminocytologic dissociation (a normal cell count with raised 
protein) which is associated with BBB dysfunction. Furthermore, the non-specific 
white matter lesions demonstrated on the MRI of the brain may have been a result of 
this inflammatory process (Figure 1).  
The aetiology of the transient paraparesis is perhaps less clear. Spinal cord venous 
infarction or congestion is a possibility, given the presence of an IMV thrombosis on 
abdominal imaging. However, the IMV drains into the inferior vena cava whereas the 
spinal cord drains into the superior vena cava. It therefore seems unlikely that spinal 
cord venous infarction or congestion is responsible for the patient’s transient 
myelopathy, especially given the rapid recovery prior to anticoagulation.  
IL-1 over-expression and demyelination within the spinal cord may offer a more 
plausible explanation, despite the lack of visible inflammation on MRI spine. It is 
conceivable that the transient nature of the paraparesis may have been due to CNS 
tachyphylaxis following chronic IL-1 stimulation. In rodents exposed to an IL-1 viral 
vector, peak cytokine expression and central nervous system dysfunction occurred at 
days eight and fourteen. However, at day thirty, despite IL-1 expression remaining 
high, all signs of inflammation were no longer present, remyelination was noted and 
the blood brain barrier was intact.[6] This supports the theory that tachyphylaxis may 
be responsible for the spontaneous resolution of the patient’s myelopathy.  
Treatment with the interleukin-1 antagonist anakinra was highly successful in this 
case. Anakinra provides complete resolution of symptoms and inflammatory response 
in more than 80% of patients with TRAPS and is therefore indicated as first line 
treatment, in patients requiring long term steroids.[7] In a population of paediatric 
patients, when anakinra was withdrawn after 15 days of treatment, the disease 
relapsed within an average of 5 days but resolved with reintroduction of anakinra. 
Therefore, long term treatment is required for continued disease remission.[8]  
 
Key Points  
1. In patients with relapsing-remitting systemic disorders and central nervous system 
involvement, very rare periodic fever syndromes such as TRAPS should be considered 
in the differential diagnosis. 
2. A thorough history and examination is required to correctly diagnose TRAPS and other 
systemic autoinflammatory diseases. 
3. Long term IL-1 blockade is completely effective in terms of controlling both symptoms 
and biomarkers of inflammation in more than 80% of TRAPS patients 
4. Patients with TRAPS should be managed in specialist centres. 
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Figure 1. MRI brain sections demonstrating non specific white matter lesions (white 
arrows). 
 
 
 
 
